Pregled bibliografske jedinice broj: 879626
Rational decision making in the allocation of extremely expensive drugs
Rational decision making in the allocation of extremely expensive drugs // 7th Adriatic and 5th Croatian congress of pharmacoeconomics and outcomes research
Poreč, Hrvatska, 2017. str. 1-3 (predavanje, međunarodna recenzija, neobjavljeni rad, znanstveni)
CROSBI ID: 879626 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Rational decision making in the allocation of
extremely expensive drugs
Autori
Diana Mance ; Davor Mance ; Dinko Vitezić
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, neobjavljeni rad, znanstveni
Skup
7th Adriatic and 5th Croatian congress of pharmacoeconomics and outcomes research
Mjesto i datum
Poreč, Hrvatska, 20.04.2017. - 23.04.2017
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
allocation, decision making, pharmacoeconomics
Sažetak
OBJECTIVES: To present a method of health- economic analysis and allocation based on a marginal approach under budget constraints. METHODS: We show that a detailed comparative a priori incremental cost-effectiveness analysis provides the necessary input for budget impact analysis about the proper order of introduction of new therapies. By arranging the therapies according to the cost-effectiveness rule and taking into account multiple constraints (most importantly the budgetary constraint), the standard of care maximises the health value for the patient. We show the method on the example of a Croatian standard of care for the treatment of hepatitis C virus (HCV) infection. Final parameters were estimated by Monte Carlo simulations. RESULTS: New HCV therapies, approved by the European Medicine Agency in 2015, have high efficacy, shorter duration, and are better tolerated than alternative interventions. Patient subpopulations were differentiated by their response to previous treatment and fibrosis METAVIR score. Depending on patient subpopulation, different therapies, including the dual therapy of pegylated interferon and ribavirin, are found to be cost- effective in comparison to alternatives. CONCLUSION: We showed that introduction of new therapies on the market based on marginal analysis would result in a significant increase of successfully treated patients under budget constraint. This economic evaluation is an example of negotiations’ starting point between pharma industry and health management organisations, as well as for an introduction of specific contracts between them.
Izvorni jezik
Engleski
Znanstvena područja
Matematika, Kliničke medicinske znanosti, Ekonomija
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Ekonomski fakultet, Rijeka,
Sveučilište u Rijeci - Odjel za fiziku